Different Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis by Holley, Aaron B. et al.
Hindawi Publishing Corporation
Thrombosis
Volume 2010, Article ID 540386, 9 pages
doi:10.1155/2010/540386
Clinical Study
DifferentFiniteDurationsof Anticoagulationand Outcomes
following IdiopathicVenousThromboembolism: A Meta-Analysis
AaronB.Holley,1 ChristopherS.King,2 Jeffrey L. Jackson,3 andLisa K.Moores3
1Department of Pulmonary/Critical Care/Sleep Medicine, Walter Reed Army Medical Center, Pulmonary/Sleep and
Critical Care Service, 6900 Georgia Avenue NW, Washington, DC 20307, USA
2Department of Pulmonary/Critical Care Medicine, William Beaumont Army Medical Center, 5005 N. Piedras Street, El Paso,
TX 79930, USA
3Department of Medicine, The Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd, Bethesda,
MD 20814, USA
Correspondence should be addressed to Aaron B. Holley, aaron.holley@amedd.army.mil
Received 4 October 2010; Accepted 15 November 2010
Academic Editor: Paolo Simioni
Copyright © 2010 Aaron B. Holley et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Introduction. Controversy remains over the optimal length of anticoagulation followingidiopathic venous thromboembolism. We
soughttodetermine ifalonger,ﬁnitecourseofanticoagulationoﬀeredadditionalbeneﬁtoverashortcourseintheinitialtreatment
of the ﬁrst episode of idiopathic venous thromboembolism. Data Extraction. Rates of deep venous thrombosis, pulmonary
embolism, combined venous thromboembolism, major bleeding, and mortality were extracted from prospective trials enrolling
patients with ﬁrst time, idiopathic venous thromboembolism. Data was pooled using random eﬀects meta-regression. Results.
Ten trials, with a total of 3225 patients, met inclusion criteria. For each additional month of initial anticoagulation, once therapy
was stopped, recurrent venous thromboembolism (0.03 (95% CI: −0.28 to 0.35); P = .24), mortality (−0.10 (95% CI: −0.24 to
0.04); P = .15), and major bleeding (−0.01 (95% CI: −0.05 to 0.02); P = .44) rates measured in percent per patient years, did
not signiﬁcantly change. Conclusions: Patients with an initial idiopathic venous thromboembolism should be treated with 3 to 6
months of secondary prophylaxis with vitamin K antagonists.At that time, a decision between continuing with indeﬁnite therapy
can be made, but there is no beneﬁt to a longer (but ﬁnite) course of therapy.
1.Introduction
Pulmonary embolism (PE) and deep venous thrombosis
(DVT)arethoughttobepart ofthesamediseaseprocess,and
together they are referred to as venous thromboembolism
(VTE). In the general population, VTE occurs in 1-2 out of
every 1000 people per year or 0.1% per person per year [1].
Anticoagulationistheprimarytreatmentforthisdisease,and
eﬃcacy is well established [2].
The prescribed duration of anticoagulation is dependent
on the risk for recurrent thromboembolic events. Good
evidence supports limited duration treatment for patients
with transient risk factors [2]. For the ﬁrst episode of
idiopathic (unprovoked) VTE, controversy remains over the
appropriate length of therapy [1–4]. The Seventh edition of
the American College of Chest Physicians Guidelines [5]o n
antithrombotic therapy recommended at least 6 to twelve
months of anticoagulation for patients with a ﬁrst idiopathic
VTE event, with consideration of indeﬁnite therapy. These
recommendations were based upon the principle that sec-
ondary prophylaxis is eﬀective (less than 1% recurrence/year
while on therapy) [3] and patients with idiopathic events
are more likely to suﬀer recurrences after anticoagulation is
discontinued [4, 6, 7].
Several systematic reviews have attempted to address
length of therapy following VTE, but none have focused
exclusively on comparing ﬁnite durations following an
idiopathic event [8–11]. In 2008, the 8th American College2 Thrombosis
of Chest Physicians (ACCP) consensus guidelines updated
treatment recommendations for the ﬁrst episode of idio-
pathic VTE [2] by modifying their previous recommen-
dation of 6–12 months treatment [5], to “at least three
months.” This change reﬂects the uncertainty surrounding
the appropriate duration for anticoagulation [12, 13].
The guidelines also recommend individualized risk strat-
iﬁcation and consideration for life-long therapy. Although
tools to estimate risk for VTE recurrence are available, they
have not been well validated in management or outcome
studies [14, 15]. For the individual patient, balancing
bleeding with recurrence risk remains diﬃcult [4]. Until
individualized risk stratiﬁcation can be done in a systematic,
reliable, and safe manner, physicians will need to decide
between ﬁnite or life-long anticoagulation in these patients.
Because physicians and patients may opt against life-long
therapy for the ﬁrst idiopathic VTE occurrence, we sought
to deﬁne the safest and most eﬀective duration for ﬁnite
therapy. Our goal was to pool studies evaluating treatment
duration following idiopathic VTE, excluding all patients
with transient or identiﬁable permanent risk factors. We
focused primarily on VTE recurrence rates after anticoagu-
lation is discontinued.
2.Methods
2.1. Literature Search. Two investigators independently
searched the published literature (1964 through January
2009) for prospective cohorts and randomized controlled
trials (RCTs) evaluating oral anticoagulation for the ﬁrst
episode of idiopathic VTE. The search was not limited to
the English language. Databases included were Medline,
EMBASE, http://ClinicalTrials.gov/,C o m p u t e rR e t r i e v a lo f
Information on Scientiﬁc Projects, Cochrane Controlled
TrialsRegistry,ACPJournalClub,Cochrane DatabaseofSys-
tematic Reviews, and Databases of Abstracts and Reviews of
Eﬀectiveness. Search terms were “deep venous thrombosis,”
“pulmonary embolism,” and “venous thromboembolism.”
Hand searching of cited bibliographies was performed for
completeness.
2.2. Study Selection Criteria. Inclusion criteria were as fol-
lows: (1) RCT or prospective cohort study enrolling patients
with an initial episode of idiopathic VTE, (2) documented
duration of anticoagulation of at least three months, (3)
documented duration of follow-up postanticoagulation, (4)
monitoring of adverse events, to include major bleeding,
recurrent VTE, and death, and (5) objective conﬁrmation of
initialandrecurrentDVT(Dopplerultrasonography,impen-
dence plethysmography, radioﬁbrinogen uptake scanning,
venography)orPE(computedtomography(CT)angiogram,
pulmonary angiogram, ventilation perfusion scanning).
Studies that included pregnant patients or patients less
than 18 years old were excluded. Data from patients with
prior episodes of VTE or transient risk factors for VTE
were excluded from the analysis. Patients who had known
malignancy, antiphospholipid antibody syndrome (APAS),
antithrombin III (ATIII) deﬁciency, or protein C or S
deﬁciencydiagnosed atthetime ofenrollment were excluded
Table 1
Study described as randomized
Appropriate randomizationmethod (i.e., random numbers table)
Study described as double blind
Appropriate blinding (i.e., identical placebo)
Description of withdrawal and dropouts
Methods of statistical analysis described
Clear description of inclusion and exclusion criteria
Description of methods to assess adverse eﬀects
from the analysis. Patients diagnosed with the Factor V
Leiden or prothrombin20210A mutationwere not excluded.
For studies that enrolled patients with both ﬁrst time,
idiopathic VTE (inclusion criteria) and those with transient
or permanent risk factors, or previous VTE (exclusion crite-
ria), attempts were made to separate outcomes data. When
this was not possible, the primary author was contacted via
email for additional information. If no response was received
within 3 weeks, a second email was sent. If the author
could not be reached and it was not possible to separate
outcomesdata, the study was excluded.Because most studies
did not systematically screen for cancer or thrombophilia
at enrollment, these conditions were occasionally diagnosed
andreported duringstudyfollow-up.The patientsdiagnosed
with cancer or thrombophilia during follow-up were not
excluded. Two authors (Christopher King and Aaron B. Hol-
ley) independently selected articles for inclusion. Disputes
regarding inclusion were presented to a third party (Lisa K.
Moores) and then resolved by consensus.
2.3. Study Quality Assessment. All studies were rated inde-
pendently for quality by two investigators (CSK and ABH)
using the index of Jadad et al. [16]f o rR C T s( Table 1).
There was 100% agreement regarding quality ratings on ﬁrst
review.
2.4. Data Extraction. The following data were extracted
from each article: mean/median age; sex distribution;
mean/median duration of anticoagulation; mean/median
durationoffollow-up following cessation ofanticoagulation;
DVT, PE, and combined VTE recurrences during and after
anticoagulation; major bleeding during and after anticoag-
ulation; and mortality rate. When bleeding data were not
available but authors were contacted, we requested they use
the following deﬁnition for major bleeding: clinically overt
and associated with either a decrease in Hgb ≥ 2g/dL or
transfusion of ≥2 units pRBCs, if it was retroperitoneal or
intracranial, or if it warranted the permanent discontinua-
tionof the study drug. Fatal bleeding eventswere includedin
the mortality rate.
Data were extracted independently by two investigators
(CSK and ABH); disagreements were settled by consensus.
Primary outcomes were VTE (DVT and/or PE) recurrence
and mortality rate, percent per patient years, after treatment
cessation. We also determined the rate of major bleeding
both on and oﬀ therapy. As a secondary outcome we createdThrombosis 3
Table 2: Characteristics of included studies.
Trial Design Patients Age (mean) %male Tx Duration (mos) Jadad Score Jadad Problems
Agnelli et al. [6] RCT 90 — — 12 6 Not double blind
91 — — 3
Agnelli et al. [7] RCT 134 67 55 12 6 Not double blind
133 68 61 3
Farraj [20] RCT 32 41 62 24 4 Not double blind
Withdrawals/dropouts
No statistics methods 32 42 56 6
Legnani et al. [24] Cohort 628 67 53 7 4 Not randomized
Kyrle et al. [22] Cohort 453 45 0 9 4 Not randomized
373 51 100 8
Palareti et al. [19] RCT 385 59 55 13.0 6 Not double blind
120 68 42 10.8
Palareti et al. [25] Cohort 282 70 55 7.5 4 Not randomized
Schulman et al. [21] RCT 289 63 63 6 6 Not double blind
Poli et al. [23] Cohort 183 60 57 14.9 3 Not randomized
an adverse eventrateconsisting ofthe rateof VTE recurrence
plus major bleeding events oﬀ of therapy.
2.5. Statistics. All event rates were converted to percent
per patient year to adjust for variations in duration of
follow-up after cessation of therapy. Data were pooled using
random-eﬀects methods. For metaregression modeling, a
restricted maximum likelihood estimator was used [17].
Sensitivity analyses were done both by stratifying on the
indicator variable and by including the term as an additional
independent variable in regression modeling.
We analyzed all outcomes as continuous variables based
on increasing duration of treatment. We also combined
studies into three diﬀerent groups based on whether they
initially received 3–6, 6–12, or >12 months of treatment.
These groups were chosen because they are commonly
recommended in guidelines and studied in trials and are
thereforeclinicallyrelevant.Outcomeswerecomparedacross
groups, and when signiﬁcance was found, pairwise com-
parisons were performed to determine where the diﬀerence
occurred.
3.Results
The initial search yielded 401 studies. Of these, 382 were
excluded, mainly because they dealt with disease processes
otherthanVTE(Figure 1).Ultimately,10studies,withatotal
of 3225 patients, met our inclusion criteria (Table 2). Two
studies were combined because one [18] reported extended
follow-up data on the same patient group enrolled in the
other [19]. The average duration of treatment was 9.7 ± 5.5
months and the average length of follow-up oﬀ of treatment
was 27.6 ± 9.1 months.
There were 6 RCTs [6, 7, 19–21]a n d4p r o s p e c t i v e
cohorts [22–25] studies, with 1306 and 1919 patients,
respectively. Of the RCTs, 4 had two arms receiving diﬀerent
durations of therapy that were both eligible for inclusion
(ﬁrst time idiopathic VTE with documented follow-up oﬀ
of therapy) [6, 7, 19, 20]. The study by Palareti et al. [19]
consisted of two groups, one with patientsthat were negative
for D-dimer at the end of treatment and the other with
patients who were D-dimer positive. The positive D-dimer
group had patients randomized to continued anticoagula-
tion or cessation of treatment. We included the D-dimer
negative group and the D-dimer positive group that was
randomized to treatment cessation in our analysis. The D-
dimer positive group that was randomized to continue anti-
coagulation had no documented follow-up oﬀ of therapy
and was therefore excluded. This group published extended
follow-up on their patients in 2009, and these data were
included as part of our analysis [18]. Lastly, one RCT had
only one arm eligible for inclusion, with the second arm
excluded because patients were treated for only 6 weeks
[21].4 Thrombosis
Table 3: Qualitative analysis.
Trial Design Population Follow-up (months) Recurrence (% idiopathic)
Agnelli et al. [6]R C T
PE, enrolled after 3 mos No
cancer/thrombophilia screening INR 2-3
(83%) New cancer 11 patients
3, 6, 12 after
randomization,then q6
84.8%
Agnelli et al. [7]R C T
DVT, enrolled after 3 mos No
cancer/thrombophilia screening INR 2-3
(81%) New cancer 5 patients
3, 6, 12 after
randomization,then q6
100%
Farraj [20]R C T DVT and PE, enrolled after event No
cancer/thrombophilia screening
q4 for 12 mos after
cessation
100% 1 event on therapy
(INR = 1.8, dose missed
during travel)
Legnani et al. [24] Cohort
DVT (71%), PE (29%) enrolled after 3
mos No cancer/thrombophilia screening
15 patients (2.4%) protein C, S def
3 mos after cessation,
then q6 mos
86%
Kyrle et al. [22] Cohort
DVT (58%) and PE (42%) enrolled after 3
mos No cancer screening, had systematic
thrombophilia screening HRT/OCP not
excluded (175 used OCPs, 61 on HRT),
females encouraged to stop after VTE New
cancer in 14 patients Distal and axillary
DVT included
q3 mos for ﬁrst year,
then q6 mos
Not speciﬁed
Palareti et al.∗ [19]R C T
Prox DVT (62%) and PE (38%) enrolled
after 3 mos ATIII+APA screening, no
cancer screen New cancer in 13 patients
q3-6 mos intervals Not speciﬁed
Palareti et al. [25] Cohort
DVT and PE, enrolled after 3 mos No
cancer/thrombophilia screening Distal
DVT included D-dimer elevated in 49.3%
3 mos after cessation,
then q6 mos
Not speciﬁed
Schulman et al. [21]R C T
DVT (86%) and PE (14%), enrolled after
event Prot C,S, ATIII screening, no cancer
screen INR goal (2.0–2.85)
1.5, 3, 6, 9, 12, and 24
mos
Not speciﬁed
Poli et al. [23] Cohort
DVT and PE, enrolled after 6 mos Prot C,S,
ATIII, APA screening (only APA excluded),
no cancer screen D-dimer elevated in 38%
Two in ﬁrst year, one
thereafter 97%
Enrolled after 3 months means that they were not recruited until after they had at least 3 months of therapy, as opposed to being recruited at the time of the
initialevent. All known cancer/thrombophilia was excluded; trialsonly got credit for systematicscreening. INR range includedfor patientswho hadap e r i o d
on therapy included. ∗Includes data from follow-up study by Cosmi et al. [18]
Overall age and percentage male, both of which would
be expected to aﬀect the VTE recurrence rate, are listed in
Table 2.Ofnote,thetrial byKyrle etal.[22]separatedgroups
by gender and showed a signiﬁcant increase in recurrences
for males. Table 3 describes additional diﬀerences that might
be expected to aﬀect outcomes. Relevant patient population
criteriaaredescribed,suchaswhetherpatientswithDVTand
PE were enrolled and the percent time that INR was in the
target range during treatment. The study by Kyrle et al. [22]
was the only one to document hormone replacement (HRT)
and oral contraceptive (OCP) use. A few studies screened
for thrombophilia prior to enrollment [19, 21–23]b u tm o s t
simply excluded patients with known disease. No studies
screened for cancer, but four studies [6, 7, 19, 22]r e p o r t e d
cancer diagnoses during follow-up.
Table 3 also lists the frequency of follow-up visits. For all
studies, patients were speciﬁcally instructed to contact inves-
tigators, or their primary doctors, for signs or symptoms of
recurrent VTE. The percentage of recurrent events that were
idiopathic is also listed in Table 3.
3.1. VTE Recurrence Rates. Table 4 lists the absolute number
of recurrences, the duration of follow-up, and the VTE event
rate in percent per patient year after therapy was stopped.
Several studies did not provide VTE events broken down
separately into DVT and PE [6, 7, 21, 22]. The majority of
studies, regardless oftherapy durationpriortocessation, had
VTE recurrence rates between 4.6 and 8.8% per patient year.
The 120 patients in the Cosmi et al. [18]a n dP a l a r e t ie ta l .
[19] study who were D-dimer positive but had treatment
withheld had a slightly higher rate of 9.6% per patient year,
while the all female arm of the Kyrle et al. [22]s t u d yh a da
lower than average rate of 2.0% per patient year. One arm
of the Farraj [20] study had only 12 months of follow-up oﬀ
treatment and the Palareti cohort [25]p r o v i d e d1 6m o n t h s .
All other studies had >22 months of follow-up oﬀ of anti-
coagulation.
Table 5 lists the change in recurrence rates for each
additional month of anti-coagulation prior to cessation. For
increasing durations of therapy, there was no signiﬁcant
change in DVT, PE, and VTE rates as measured in percentThrombosis 5
Potentially relevant studies identiﬁed and
screened for retrieval after Medline search
(n = 401) Studies excluded (n = 382)
21 Prophylaxis
19 Peri-op anticoagulation
11 Acute treatment only
11 Treatment with IVC ﬁlters
10 Diagnosis VTE
7 VTE other than 1st time idiopathic
Studies retrieved for more detailed
evaluation (n = 19)
Additional studies identiﬁed by
reference lists (n = 6) Studies excluded (n = 16)
unavailable
3 Duplicate data
6 Disease not idiopathic VTE
Studies included in meta-
analysis (n = 10)
1 No follow-up oﬀ therapy
220 Disease other than VTE 13 Pregnancy/pediatrics
33 Reviews/case reports
27 Monitoring/management
10 Lytics/DTIs
Additional studies identiﬁed by
search of EMBASE, DARE,
CCRT, CRISP, CDSR,
Club (n = 1)
6 No author response/data
http:// clinicaltrials.gov/, ACP journal
Figure 1
4.37 (0.89, 7.84)
6.25 (0, 14.64)
4.64 (1.43, 7.85)
4.86 (3.63, 6.09)
6.19 (3.38, 9)
6.28 (1.76, 10.8)
5.15 (4.05, 6.24)
6.25 (0, 14.64)
4.13 (2.15, 6.12)
5.27 (2.04, 8.51)
4.44 (3.4, 5.5)
01 5
DVT recurrence rate (% per patient per year)
D V Tr a t e( 9 5 %C I )
3–6months
Agnelli et al. [7]
Farraj [20]
Subtotal (I2 = 0%)
6–12months
Legnani et al. [24]
Palareti et al. [25]
Palareti et al. [19]∗
Subtotal (I2 = 0%)
>12months
Farraj [20]
Palareti et al. [19]
Poli et al. [23]
Subtotal (I2 = 0%)
∗Includes data from follow-up study by Cosmi et al. [18]
P value for diﬀerence across groups .58
Figure 2: DVT recurrence rates after treatment cessation.
per patient years. Figures 2, 3,a n d4 show recurrence rates
oﬀ of therapy in peto-plots, based on whether patients
initially received 3–6, 6–12, or >12 months of therapy.
Pairwise comparisons between groups were also performed,
and no signiﬁcant diﬀerences in recurrence rates were
found.
0.73 (0, 1.55)
2.5 (0, 5.92)
0.82 (0.03, 1.62)
1.19 (0.57, 1.82)
2.32 (0.82, 3.82)
2.76 (0.87, 4.66)
1.81 (0.81, 2.81)
0 (0, 0.83)
0.89 (0.31, 1.46)
1.38 (0.28, 2.47)
0.72 (0.01, 1.43)
PE rate (95% CI)
06
PE occurrence rate % per patient per year
3–6months
Agnelli et al. [7]
Farraj [20]
Subtotal (I2 = 0%)
6–12months
Legnani et al. [24]
Palareti et al. [25]
Palareti et al. [19]∗
Subtotal (I2 = 47.3%)
>12months
Farraj [20]
Palareti et al. [19]
Poli et al. [23]
Subtotal (I2 = 0%)
∗Includes data from follow-up study by Cosmi et al. [18]
P value for diﬀerence across groups .5
Figure 3: PE recurrence rates after treatment cessation.
3.2. Bleeding Rates. Table 4 lists bleeding rates oﬀ therapy.
Generally,bleedingwasconsidered“major” ifitwasclinically
overt and associated with either a decrease in Hgb ≥ 2g/dL
or transfusion of ≥2 units pRBCs, if it was retroperitoneal or
intracranial,or ifitwarrantedthepermanentdiscontinuation
of the study drug [6, 7]. Farraj [20], Palareti et al. [19],6 Thrombosis
Table 4: Primary outcome events following cessation of therapy.
Trial Patients Tx (mos) f/u (mos) DVT PE VTE Bleeding Mortality Adverse
Agnelli et al. [6]∗ 90 12 26.4 — — 10 (5.1) 0 (0) 8 (3.1) 10 (5.1)
91 3 31.7 — — 11(4.6) 1 (0.4) 7 (2.9) 12 (5.0)
Agnelli et al. [7]∗ 134 12 29.4 — — 17 (5.2) 0 (0) 7 (1.7) 17 (5.2)
133 3 37.2 18 (4.4) 3 (0.7) 21 (5.1) 2 (0.5) 7 (1.7) 23 (5.6)
Farraj [20] 32 24 12 2 (6.3) 0 (0) 2 (6.3) 0 (0) 0 (0) 2 (6.3)
32 6 30 5 (6.3) 2 (2.5) 7 (8.8) 0 (0) 0 (0) 7 (8.8)
Legnani et al. [24] 628 7 22.4 57 (5.5) 14 (1.3) 71 (6.8) 0 (0) 11 (1.1) 71 (6.8)
Kyrle et al. [22]∗ 453 9 38 — — 28 (2.0) 0 (0) — 28 (2.0)
373 8 33 — — 74 (7.2) 0 (0) — 74 (7.2)
Palareti et al. [19]∗∗ 385 13.0 31.6 42 (4.1) 9 (0.9) 51 (5.0) 0 (0) 6 (0.6) 51 (5.0)
120 10.8 28.7 20 (6.3) 8 (2.8) 28 (9.6) 0 (0) 2 (0.7) 28 (9.6)
Palareti et al. [25] 282 7.5 16.5 24 (6.2) 9 (2.3) 33 (8.5) 0 (0) — 33 (8.5)
Schulman et al. [21] 289 6 42 — — 55 (5.4) 0 (0) 31 (2.7) 55 (5.4)
Poli et al. [23] 183 14.9 28.6 23 (5.3) 6 (1.4) 29 (6.6) 0 (0) 3 (0.7) 29 (6.6)
( ):%perpatientyears,f/uis total,documenteddurationoﬀ oftherapy;VTE: DVT and PEcombined;Adverse Outcomes:VTE andmajor bleeding;Bleeding:
see text for individual study deﬁnition of major bleeding
Major generallydeﬁned asclinicallyovert andassociatedwitheitheradecreaseHgb ≥ 2g/dLortransfusion≥2unitspRBCs,ifretroperitonealor intracranial,
or if warranted the permanent discontinuationof the study drug.
∗VTE could not be separated into DVTs and PEs.
∗∗Includes data from follow-up studyby Cosmi et al. [18]
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VTE recurrence rate
3–6months
Agnelli et al. [7]
Agnelli et al. [6]
Farraj [20]
Schulman et al. [21]
Subtotal (I2 = 0%)
6–12months
Agnelli et al. [7]
Agnelli et al. [6]
Kyrle et al. [22]
Kyrle et al. [22]
Legnani et al. [24]
Palareti et al. [25]
Palareti et al. [19]∗
Subtotal (I2 = 92.3%)
>12months
Farraj [20]
Palareti et al. [19]
Poli et al. [23]
Subtotal (I2 = 0%)
∗Includes data from follow-up study by Cosmi et al. [18]
P value for diﬀerence across groups .82
Figure 4: VTE recurrence rates after treatment cessation.
and Cosmi et al. [18] used the same deﬁnition but did not
include “bleeds warranting permanent discontinuation of
the study drug.” Schulman et al. [21] deﬁned major as “any
bleeding requiring hospitalization, treatment with vitamin
K, treatment with blood, or both.” Neither Kyrle et al. [22],
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4.04 (1.76, 7.81)
0.94 (0.47, 1.67)
0.69 (0.08, 2.48)
1.33 (0.42, 2.25)
0 (0, 10.89)
0.59 (0.22, 1.28)
0.69 (0.14, 2)
0.61 (0.15, 1.07)
Mortality (95% CI)
01
Mortality rate
3–6months
Agnelli et al. [7]
Agnelli et al. [6]
Farraj [20]
Schulman et al. [21]
Subtotal (I2 = 55.7%)
6–12months
Agnelli et al. [7]
Agnelli et al. [6]
Legnani et al. [24]
Palareti et al. [19]∗
Subtotal (I2 = 47.5%)
>12months
Farraj [20]
Palareti et al. [19]
Poli et al. [23]
Subtotal (I2 = 0%)
∗Includes data from follow-up study by Cosmi et al. [18]
∗∗P value for diﬀerence across groups .03
Figure 5: Mortality rate
Poli et al. [23], nor Palareti et al. [25] systematically assessed
for bleeds, but via correspondence all three conﬁrmed that
no major bleeds(accordingto ourpredetermined deﬁnition)
were recorded after therapy was stopped.
Several factors might be expected to alter bleeding rates
across studies. Some investigators used the presence of a
previous bleed on anticoagulation as part of their exclusion
criteria, which would bias these studies toward having fewer
bleeding events than the others. Although only the two
Agnelli et al. [6, 7] studies speciﬁcally stated that theyThrombosis 7
Table 5: Rate change (following cessation) for each additional
month of initial anticoagulation.
Events Rate (95% CI) ppy P-value
DVT −0.01 (−0.23 to 0.21) .94
PE −0.05 (−0.15 to 0.04) .23
VTE 0.03 (−0.28 to 0.35) .24
Bleed (on) −0.23 (−1.22 to 0.75) .75
Bleed (oﬀ) −0.01 (−0.05 to 0.02) .44
Deaths −0.10 (−0.24 to 0.04) .15
Rates measured in percent per patient year.
excluded such patients, one would assume that any study
that randomized patients to extended treatment after an
initial period of therapy would have done the same for
ethical reasons [19]. Target INR in the Schulman et al. [21]
study was only 2.0–2.85, while all others targeted 2.0-3.0.
Some studies included patients on acenocoumarol [6, 7]o r
dicumarol [21] as well as Coumadin. The lack of formal
assessment forbleedingintheKyrleetal.[22],Polietal.[23],
and Palareti et al. [25] studies means that their results likely
underestimated bleeding.
Most studies enrolled patients after treatment had
already been stopped, and only 4 had data available for
bleeding rates while on anti-coagulation [6, 7, 20, 21]. Very
few bleeds oﬀ of therapy were recorded, which is consistent
with a lack of persistent elevation in bleeding risk once anti-
coagulation is stopped. Table 5 lists the change in bleeding
rates both on, when available, and oﬀ of therapy. As was
the case with thromboembolic recurrence rates, there was
no signiﬁcant change in the bleeding rate, as measured in
percentperpatientyears,witheachadditionalmonthofanti-
coagulation, regardless of whether the patient was on or oﬀ
anticoagulation.
3.3. Adverse Events Combined. Only 4 studies had data for
bleeding and recurrence rates, both on and oﬀ of therapy
[6, 7, 20, 21]. This made our datadiﬃcult to analyze in terms
of balancing the excess bleeding expected from extending
therapy with any possible beneﬁt in reducing VTE once
therapy is stopped. Both of the Agnelli et al. [6, 7] studies
found that longer durations increased the number of bleeds
but did not reduce VTE rate at two years. The Farraj [20]
study did show a beneﬁt for 24 versus 6 months of anti-
coagulation, with recurrence rates of 6.3% versus 8.8% per
patientyear, oﬀoftherapy,respectively (Table 4).Each group
suﬀered 2 bleeds while on therapy, and no bleeds oﬀ of
therapy. This study had fewer patients and a lower Jadad
score when compared to the Agnelli et al. studies (Table 2),
and the arm that received 24 months of anti-coagulation
had only 12 months of follow-up recorded oﬀ of therapy.
The Schulman et al. study compared 6 months to 6 weeks
of therapy, and only patients in the 6 month arm met our
inclusion criteria. There were 3 bleeds while on therapy in
the 6 month arm (2.1% per patient year) [21].
Otherwise, analysis ofthecombinedoutcomeofbleeding
and VTE recurrence oﬀ of therapy was limited by the small
number of bleeds. Comparing the combined outcome was
essentially a repeat assessment of the VTE recurrence rate
across studies.
3.4. Mortality. Following treatment cessation, we found
no statistically signiﬁcant decrease in mortality rate with
extension of initial therapy duration (Table 5). Most studies
were speciﬁc in attributing death to either bleeding, VTE,
or another cause. However, it was not clear how long each
patient was treated with anti-coagulation prior to death, and
whether or not they were on therapy when they died. Forthe
Palareti et al. [25]a n dK y r l ee ta l .[ 22] studies, no mortality
data is listed because deaths could not reliably be assigned to
as p e c i ﬁ cg r o u p( Table 4).
Figure 5 displays mortality diﬀerences in a Peto-plot,
based on whether patients initially received 3–6, 6–12, or
>12 months of therapy. The diﬀerence in mortality across
groups was statistically signiﬁcant. In pairwise comparisons,
there was a trend toward a signiﬁcant decrease when the >12
was compared with the 3–6 month group (P = .05), but no
diﬀerence when the >12 was compared to the 6–12 month
group (P = .32).
3.5. Additional Analyses. We reanalyzed our data looking at
cohort studies versus RCTs, studies with Jadad ≤4v e r s u s>4,
cohort age, and the percentage of each cohort that was male.
For all outcome events, changes in rates with extensions of
therapy were not statistically signiﬁcant.
Two additional RCTs that enrolled patients with idio-
pathic VTE but met exclusion criteria, one because several
patients in one arm were diagnosed with APAS at enrollment
[26]and theotherbecause onethird ofpatientshad previous
VTE [27], were added back to see if their inclusion would
impact our results. For each additional month of anticoagu-
lation, there was still no statistically signiﬁcant decrease in
DVT, PE, VTE, or major bleeding rates after therapy was
stopped. There was a trend toward reduced mortality with
longer durations of treatment (P = .09). When duration of
therapy was categorized in 3 diﬀerent groups, 3–6, 6–12, and
>12 months, there were no signiﬁcant diﬀerences in DVT,
PE, VTE, or major bleeding rates. Pairwise comparisons for
mortality again showed signiﬁcantly lower rates for patients
treated >12 months in comparison to 3–6, but not to 6–12
months.
4.Discussion
Controversy surrounds the optimal duration of secondary
prophylaxis with anticoagulation in patients with an initial
idiopathic event. Studies over the past decade have been
consistent in the ﬁnding that therapy is eﬀective, and
recurrent VTE is rare while on anticoagulation. However,
anywhere from 8–20%ofpatientswill experience a recurrent
event within 10 years of stopping anticoagulation [6, 12,
21]. Recurrence rates depend on patient-related factors
surrounding the initial event. Patients whose initial event is
idiopathic have a higher rate of recurrence, [6, 28]w h i c h
makes this a population of great interest.8 Thrombosis
Several systematic reviews have attempted to address
length of therapy following VTE, but none have focused
exclusively on comparing ﬁnite durations following an
idiopathic event [8–11]. Ours is the ﬁrst systematic review
and quantitative assessment to do so. We have found that
recurrence rates after discontinuation of anticoagulation
are not dependent on the duration of the initial course
of therapy. There is no statistically or clinically signiﬁcant
decrease in recurrence with longer (but ﬁnite) courses of
anticoagulation.
To balance the beneﬁts and risks of extending antico-
agulation, we attempted to capture major bleeding rates,
and an adverse event rate deﬁned as a combination of
recurrent VTE and bleeding. Unfortunately, only three of the
included studies [6, 7, 20] allow any direct comparison of
bleeding rates both on and oﬀ of therapy in two separate
arms, making it diﬃcult to quantitatively assess the balance
between excess bleeding risk and recurrent VTE for a given
duration of treatment. Therefore, the focus of our review was
on outcomes after discontinuation of therapy, and bleeding
rates were expectedly low during this period. Still, it is
clear from the Agnelli et al. [6, 7] and Schulman et al.
[21] studies that extended durations increase the absolute
numberofbleeds.BecausewecouldnotﬁndabeneﬁtinVTE
reduction with ﬁnite durations greater than 3 to 6 months,
the excess bleeding risk during extended, ﬁnite therapy poses
unnecessary risk.
Our study suﬀers from several limitations. There is
signiﬁcant heterogeneity among studies included in this
analysis. The diﬀerences in baseline patient risk factors
that are outlined in Table 3 account for some of the rate
diﬀerences across studies. We attempted to address this by
using a random eﬀects model and by performing several
sensitivity analyses. In addition, we used a mean duration of
initial treatment for each study, rather than trying to obtain
patient level data. This assumes that the mean duration
applies to all patients in the study, when, in reality, several
of the studies [19, 24, 25] included signiﬁcant numbers of
patients that would have fallen into each category — 3–6, 6–
12, and >12 months. Finally, if we were unable to contact
authors for information that would separate outcomes from
provokedor unprovoked,the study was excluded.We cannot
exclude the possibility that this data may have altered
the ﬁnal analysis. Our study is also limited by the same
shortcomings that may aﬀect all meta-analyses. Publication
biasmay havelimited data on studieswhere outcomedid not
diﬀer between diﬀerent durations of anticoagulation. There
isalsothepossibilitythat relevant studieswere not identiﬁed,
although we feel that the likelihood of this was low as the
search was independently performed by two investigators.
Mortality estimates must be viewed with caution as the
overall numbers were small and it was often diﬃcult to
determine treatment duration and whether deaths occurred
on or oﬀ therapy. For the studies in which cause of death
could be deﬁnitively determined and assigned to a speciﬁc
group, only a fraction of the total was due to VTE or major
bleeding: Agnelli et al. 2001 [7]: 0/14; Legnani et al. 2006
[24]: 2/11; Palareti et al. 2006 [19]: 1/8; Kearon et al. 1999:
1/3 [26]; Ridker et al.: 3/8 [27].
The Palereti et al. [19] trial may have biased the results
in favor of a longer duration of therapy. For the purposes
of our analysis, the Palareti et al. [19]s t u d yw a sb r o k e nu p
into two arms, one treated for 10.8 months and consisting
of patients positive for D-dimer, and one treated for 13.0
months and consisting of patients negative for D-dimer
(Table 4). Because positive D-dimer is a recognized marker
for increased VTE recurrence risk [29], including this study
would favor >12monthsover<12monthsoftreatment, even
though this diﬀerence is more likely due to patient selection
than treatment duration.
The short duration of follow-up in the 24-month
treatment arm of the Farraj [20]s t u d ym a ya l s oh a v e
biased results. The 12 months of follow-up provided for
this arm were signiﬁcantly less than the average across
includedstudies(27.6 ±9.1months). Immediately following
treatmentcessationtheVTErecurrencerateusuallyincreases
[6, 7, 9, 10] and then tapers oﬀ over time. For example,
Agnelli found that two thirds of all VTE recurrences occur
in the ﬁrst year after stopping anti-coagulation [7]. Follow-
up beyond 12 months may have decreased the recurrence
rate for this arm. Otherwise, the long average duration of
follow-up oﬀ therapy for studies in our analysis is a deﬁnite
strength.
Inconclusion,ouranalysisconﬁrmsthatacrossthebroad
spectrum of patients considered to have idiopathic VTE,
extending anti-coagulation beyond three to six months will
not decrease recurrence risk after therapy is stopped. As
our ability to tailor therapy based on individualized risk
factors improves, ﬁnite durations for speciﬁc groups may be
identiﬁed. Untilthen,a generalbleedingand VTE recurrence
risk assessment should occurafter theinitial 3 to6months of
anticoagulation, with the understanding that extended but
less than life-long anti-coagulation may increase the short-
term bleeding risk without decreasing the long-term VTE
recurrence rate.
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